July 13, 2022 Few biopharma risers stand out at the half year A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
February 25, 2022 Go or no go? Bristol’s Lag3 debut March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
